Latest Developments in Global Multiple Hereditary Exostosis Market

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Buy Now Buy Now Inquire Before Buying Inquire Before Free Sample Report Free Sample Report

Latest Developments in Global Multiple Hereditary Exostosis Market

  • Pharmaceutical
  • Upcoming Report
  • Feb 2025
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

  • In January 2023, Ipsen entered into acquisition of Albireo, enhancing its rare disease portfolio with Bylvay (odevixibat), the first approved treatment for progressive familial intrahepatic cholestasis. This strategic move aims to accelerate growth in rare pediatric liver diseases, bolstering Ipsen’s market presence and expanding treatment options for underserved patients.

Frequently Asked Questions

The market is segmented based on Segmentation, By Type (Sessile and Pedunculated), Treatment (Surgery, Medication, and Others), Diagnosis (X-ray, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Genetic Tests, and Others), Site (Legs, Arms, Shoulders, Pelvis, Fingers, and Toes), Age Group (Pediatric and Adult), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) - Industry Trends and Forecast to 2032. .
The Global Multiple Hereditary Exostosis Market size was valued at USD 125.53 USD Million in 2024.
The Global Multiple Hereditary Exostosis Market is projected to grow at a CAGR of 3.7% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada, and Mexico, Germany, U.K., France, Italy, Spain, Russia, Turkey, Switzerland, Belgium, Netherland, Denmark, Sweden, Poland, Norway, Finland, and Rest of Europe, Japan, China, South Korea, India, Singapore, Thailand, Indonesia, Malaysia, Philippines, Taiwan, Vietnam, New Zealand, Australia, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Egypt, Saudi Arabia, Kuwait, Qatar, Oman, Bahrain, U.A.E., and Rest of Middle East and Africa.